News
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company ...
The Dons finished last season with a Scottish Cup success, but their form in general was dreadful, while Hearts have won all ...
Avantor missed Q2 EPS expectations as weak bioprocessing sales and customer disruptions pressured earnings, despite flat organic growth and a CEO change.
In CCC v AAC [2025] HKCFI 2987, Sir William Blair, sitting as Deputy High Court Judge in the Hong Kong Court of First Instance (“Court”), rejected ...
Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...
Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...
Chief Financial Officer Sachin Mehra said Mastercard is seeing a "strong consumer," which he attributed to factors such as low unemployment, high wages and the wealth effect. Spending has been healthy ...
Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...
Mastercard shares are up about 6% so far this year, which Jeffrey flagged was about 5 percentage points behind Visa's stock gain. "We contend that a strong global economy will power a catch-up trade," ...
Meta's strong earnings report sent its stock soaring after hours. The company also made it clear that the AI talent wars come ...
Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results